Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model
Second-generation oral mucosal vaccine candidate (VXA-H5-02) induced robust cross-neutralizing antibodies, significantly reduced viral load, and completely